iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
159 hedge funds and large institutions have $1.17B invested in iTeos Therapeutics in 2022 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 50 increasing their positions, 41 reducing their positions, and 11 closing their positions.
391% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 11
35% more funds holding
Funds holding: 118 → 159 (+41)
22% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 41
6.88% more ownership
Funds ownership: 94.71% → 101.59% (+6.9%)
25% less capital invested
Capital invested by funds: $1.55B → $1.17B (-$387M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
83% less call options, than puts
Call options by funds: $343K | Put options by funds: $2.07M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$62.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$50.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$34.5M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$24.4M |
| 5 |
Morgan Stanley
New York
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$67.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$44.7M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$41.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.3M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$12.7M |
ITOS Hedge Fund Activity: Q1 2022 in Review
159 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q1 2022, worth a combined $1.17B — down 25% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ITOS positions and 11 closed out — a net gain of 43 holders — while 50 added to existing stakes and 41 trimmed.
The largest buyer was BlackRock, adding an estimated $62.4M. The largest seller was RTW Investments, cutting an estimated $67.7M.
- 159 institutional investors held iTeos Therapeutics (ITOS) as of Q1 2022, up from 118 in Q4 2021.
- Funds reported $1.17B of iTeos Therapeutics stock for Q1 2022, down 25% quarter-over-quarter.
- 54 funds opened new iTeos Therapeutics positions in Q1 2022 and 11 closed out, a net change of +43 holders.
- The largest iTeos Therapeutics buyer in Q1 2022 was BlackRock, an estimated $62.4M added.
- The largest iTeos Therapeutics seller in Q1 2022 was RTW Investments, an estimated $67.7M sold.
Based on aggregated 13F filings for Q1 2022.